BioCentury | Sep 25, 2020
Finance

Human genetics leading the pull of investors into neuro

...two companies —Redpin Therapeutics Inc. and Coda Biotherapeutics Inc. ...
...of its financings —in Biointervene Inc., Coda Biotherapeutics Inc....
BioCentury | Mar 27, 2020
Emerging Company Profile

Redpin debuts chemogenetic platform for neurology, raises $15.5M

...there, represents a major step towards achieving those goals of better control over CNS diseases.” Coda Biotherapeutics Inc....
BioCentury | Feb 8, 2020
Product Development

Feb. 7 Product Development Quick Takes: Myriad tumbles on revenue miss; plus Verana, Sanofi, VIB, Coda, Blueprint

...preclinical studies of the therapy. Coda moves chemogenetic therapies close to clinic with Attenua acquisition Coda Biotherapeutics Inc....
BioCentury | Nov 23, 2019
Company News

Management tracks: Sanofi head of strategy Mansuri set to retire; plus Arrakis, MorphoSys, Kymera, Kronos, Kite, Twist, Cerevel, Coda, Science 37, and more

...last year to develop the pharma’s discontinued neurological disease pipeline (see “Springing into Cerevel” ). Coda Biotherapeutics Inc....
...served as CEO from 2010-18. Elizabeth S. Eaton, Staff Writer Sanofi MorphoSys AG Kymera Therapeutics Inc. Kronos Bio Inc. Arrakis Therapeutics Inc. Coda Biotherapeutics Inc. Kite...
BioCentury | Nov 5, 2019
Finance

Coda’s chemogenetics convinces investors to re-up in series A extension

...MPM Capital and Astellas Venture Management also participated. Versant’s Tom Woiwode told BioCentury the progress Coda Biotherapeutics Inc....
...typical in the current biotech investment environment of $30 million-plus, he added. Elizabeth S. Eaton, Staff Writer Coda Biotherapeutics Inc. Versant...
BioCentury | Sep 14, 2018
Finance

Coda’s chemogenetic control

...at Amgen Inc. (NASDAQ:AMGN). Woiwode, Finer and MPM’s Todd Foley joined the board. Virginia Li, Assistant Editor Coda Biotherapeutics Inc. chemogenetics gene...
BioCentury | Sep 14, 2018
Financial News

MPM, Versant launch gene therapy play Coda

...and MPM’s Mitchell Finer and Todd Foley joined the board. Coda Biotherapeutics Inc., South San Francisco, Calif. Virginia Li Coda Biotherapeutics Inc. MPM...
BioCentury | Sep 12, 2018
Financial News

MPM, Versant launch gene therapy play Coda

...to 2003. Versant’s Tom Woiwode and MPM’s Mitchell Finer and Todd Foley joined the board. Virginia Li Neuropathy Coda Biotherapeutics Inc. MPM...
Items per page:
1 - 8 of 8
BioCentury | Sep 25, 2020
Finance

Human genetics leading the pull of investors into neuro

...two companies —Redpin Therapeutics Inc. and Coda Biotherapeutics Inc. ...
...of its financings —in Biointervene Inc., Coda Biotherapeutics Inc....
BioCentury | Mar 27, 2020
Emerging Company Profile

Redpin debuts chemogenetic platform for neurology, raises $15.5M

...there, represents a major step towards achieving those goals of better control over CNS diseases.” Coda Biotherapeutics Inc....
BioCentury | Feb 8, 2020
Product Development

Feb. 7 Product Development Quick Takes: Myriad tumbles on revenue miss; plus Verana, Sanofi, VIB, Coda, Blueprint

...preclinical studies of the therapy. Coda moves chemogenetic therapies close to clinic with Attenua acquisition Coda Biotherapeutics Inc....
BioCentury | Nov 23, 2019
Company News

Management tracks: Sanofi head of strategy Mansuri set to retire; plus Arrakis, MorphoSys, Kymera, Kronos, Kite, Twist, Cerevel, Coda, Science 37, and more

...last year to develop the pharma’s discontinued neurological disease pipeline (see “Springing into Cerevel” ). Coda Biotherapeutics Inc....
...served as CEO from 2010-18. Elizabeth S. Eaton, Staff Writer Sanofi MorphoSys AG Kymera Therapeutics Inc. Kronos Bio Inc. Arrakis Therapeutics Inc. Coda Biotherapeutics Inc. Kite...
BioCentury | Nov 5, 2019
Finance

Coda’s chemogenetics convinces investors to re-up in series A extension

...MPM Capital and Astellas Venture Management also participated. Versant’s Tom Woiwode told BioCentury the progress Coda Biotherapeutics Inc....
...typical in the current biotech investment environment of $30 million-plus, he added. Elizabeth S. Eaton, Staff Writer Coda Biotherapeutics Inc. Versant...
BioCentury | Sep 14, 2018
Finance

Coda’s chemogenetic control

...at Amgen Inc. (NASDAQ:AMGN). Woiwode, Finer and MPM’s Todd Foley joined the board. Virginia Li, Assistant Editor Coda Biotherapeutics Inc. chemogenetics gene...
BioCentury | Sep 14, 2018
Financial News

MPM, Versant launch gene therapy play Coda

...and MPM’s Mitchell Finer and Todd Foley joined the board. Coda Biotherapeutics Inc., South San Francisco, Calif. Virginia Li Coda Biotherapeutics Inc. MPM...
BioCentury | Sep 12, 2018
Financial News

MPM, Versant launch gene therapy play Coda

...to 2003. Versant’s Tom Woiwode and MPM’s Mitchell Finer and Todd Foley joined the board. Virginia Li Neuropathy Coda Biotherapeutics Inc. MPM...
Items per page:
1 - 8 of 8